Toripalimab; Etoposide

Phase 2

HHenan Cancer Hospital

Toripalimab; Etoposide is one of 4 therapeutic programs targeting SCLC, Extensive Stage. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SCLC, Extensive StageNot yet recruiting

SCLC, Extensive StagePhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in SCLC, Extensive Stage

#DrugCompanyPhaseTrials

YL201

MMediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3

1 2

Serplulimab

Shanghai Henlius Biotech

Phase 3

1 3

Biological

NNational Environment Agency, Singapore

Phase 1

1 4

Toripalimab; Etoposide

HHenan Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

SCLC, Extensive Stage

NCT07698054

Clinical

Trials by Indication[1]

SCLC, Extensive Stage1 trial

A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07698054·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Toripalimab; Etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Toripalimab; Etoposide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Henan Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: HHenan Cancer Hospital

Toripalimab; Etoposide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

SCLC, Extensive Stage1 trial

References

Drug Info

Quick Facts

Related News